Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have been assigned an average rating of “Hold” from the six brokerages that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $12.00.

Several analysts have recently weighed in on XERS shares. Wall Street Zen downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Barclays raised their price objective on shares of Xeris Biopharma from $9.00 to $12.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. Finally, Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th.

Xeris Biopharma Price Performance

Xeris Biopharma stock opened at $8.58 on Thursday. Xeris Biopharma has a 12 month low of $5.25 and a 12 month high of $10.08. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. The business has a 50 day simple moving average of $8.37 and a 200-day simple moving average of $6.96. The stock has a market capitalization of $1.56 billion, a PE ratio of -78.00 and a beta of 0.70.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The firm had revenue of $92.10 million during the quarter, compared to analysts’ expectations of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. Equities analysts predict that Xeris Biopharma will post 0.07 earnings per share for the current year.

Insider Transactions at Xeris Biopharma

In other news, insider Beth Hecht sold 16,666 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $8.49, for a total value of $141,494.34. Following the completion of the sale, the insider directly owned 1,127,796 shares of the company’s stock, valued at $9,574,988.04. This trade represents a 1.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin Mcculloch sold 90,000 shares of Xeris Biopharma stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $8.03, for a total value of $722,700.00. Following the completion of the sale, the insider owned 1,691,126 shares in the company, valued at approximately $13,579,741.78. This trade represents a 5.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 224,998 shares of company stock valued at $1,847,219. Corporate insiders own 4.35% of the company’s stock.

Hedge Funds Weigh In On Xeris Biopharma

Institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in shares of Xeris Biopharma in the 2nd quarter valued at about $115,042,000. Vanguard Group Inc. increased its holdings in Xeris Biopharma by 13.8% in the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after buying an additional 1,358,760 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Xeris Biopharma by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock valued at $33,571,000 after acquiring an additional 135,815 shares during the period. State Street Corp lifted its position in shares of Xeris Biopharma by 10.1% during the 4th quarter. State Street Corp now owns 4,116,924 shares of the company’s stock valued at $32,318,000 after acquiring an additional 378,595 shares during the period. Finally, Qube Research & Technologies Ltd lifted its position in shares of Xeris Biopharma by 6.0% during the 3rd quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock valued at $26,657,000 after acquiring an additional 185,063 shares during the period. 42.75% of the stock is owned by institutional investors and hedge funds.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.